Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Clinical utility of a glycosylated fibronectin test (LumellaTM) for assessment of impending preeclampsia

GC. Di Renzo, M. Arduini, JL. Bartha, A. Froeliger, JS. Jorgensen, M. Kacerovsky, P. Stanirowski, M. Wielgos, L. Gao, MG. Gravett

. 2025 ; 38 (1) : 2474674. [pub] 20250307

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, pozorovací studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009255

OBJECTIVE: Preeclampsia is a major pregnancy complication that results in significant maternal and infant mortality and morbidity, yet difficulties remain in the diagnosis of preeclampsia based on clinical parameters alone. The objective was to assess the performance of a hand-held point-of-care (POC) immunoassay in a clinical environment for glycosylated fibronectin (GlyFn) for the prediction of preeclampsia within 4 weeks of sampling. METHODS: Multinational European prospective observational pilot study of predominantly high-risk patients in the second half of pregnancy to assess a point-of-care immunoassay for GlyFn in predicting preeclampsia within 4 weeks of sampling. GlyFn was measured using a second generation hand held POC immunoassay. Results were considered normal for GlyFn concentrations of < 350 μg/mL, positive for GlyFn concentrations of 351-600 μg/mL, and high-positive for GlyFn concentrations > 600 μg/mL. RESULTS: Preeclampsia developed in 16 (19%) of 84 subjects and was associated with a shorter gestational age at delivery 35.3 weeks vs. 37.3 weeks for non-preeclamptics, n = 82; p = 0.001), a higher risk of fetal growth restriction (FGR; 31.2% vs. 10.3% for non-preeclamptics, p = 0.046), and an increased risk of preterm birth < 37 weeks gestation (83.3% vs. 33.3% for non-preeclamptics, (n = 78; p = 0.003). GlyFn positive or high positive was seen in 13/16 (81%) and in 35/68 (51.5%), yielding a sensitivity of 81%, a specificity of 49%, a positive predictive value of 27%, and a negative predictive value of 92%. GlyFn positive or high positive was also associated with preterm birth < 37 weeks in singleton pregnancy non-preeclamptic patients. Preterm birth occurred in 4.8% of those with normal GlyFn, in 26.7% with positive GlyFn, and in 50% of those with high GlyFn in singleton gestations without preeclampsia (p = 0.008). CONCLUSION: The ability to use this test in a POC format provides a method for practitioners to quickly determine risk for preeclampsia in their pregnant patients and offers an affordable alternative, as a single analyte to other diagnostic or screening tests that require laboratory-based testing or ultrasound equipment. Independent of preeclampsia, an elevated GlyFn was also correlated with preterm delivery and requires further study.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009255
003      
CZ-PrNML
005      
20250429134927.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/14767058.2025.2474674 $2 doi
035    __
$a (PubMed)40051335
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Di Renzo, Gian Carlo $u PREIS School (The Permanent International and European School of Perinatal, Neonatal and Reproductive Medicine), Florence, Italy $u Department of Obstetrics, Gynecology and Perinatal Medicine, IM Sechenov First State University, Moscow, Russia
245    10
$a Clinical utility of a glycosylated fibronectin test (LumellaTM) for assessment of impending preeclampsia / $c GC. Di Renzo, M. Arduini, JL. Bartha, A. Froeliger, JS. Jorgensen, M. Kacerovsky, P. Stanirowski, M. Wielgos, L. Gao, MG. Gravett
520    9_
$a OBJECTIVE: Preeclampsia is a major pregnancy complication that results in significant maternal and infant mortality and morbidity, yet difficulties remain in the diagnosis of preeclampsia based on clinical parameters alone. The objective was to assess the performance of a hand-held point-of-care (POC) immunoassay in a clinical environment for glycosylated fibronectin (GlyFn) for the prediction of preeclampsia within 4 weeks of sampling. METHODS: Multinational European prospective observational pilot study of predominantly high-risk patients in the second half of pregnancy to assess a point-of-care immunoassay for GlyFn in predicting preeclampsia within 4 weeks of sampling. GlyFn was measured using a second generation hand held POC immunoassay. Results were considered normal for GlyFn concentrations of < 350 μg/mL, positive for GlyFn concentrations of 351-600 μg/mL, and high-positive for GlyFn concentrations > 600 μg/mL. RESULTS: Preeclampsia developed in 16 (19%) of 84 subjects and was associated with a shorter gestational age at delivery 35.3 weeks vs. 37.3 weeks for non-preeclamptics, n = 82; p = 0.001), a higher risk of fetal growth restriction (FGR; 31.2% vs. 10.3% for non-preeclamptics, p = 0.046), and an increased risk of preterm birth < 37 weeks gestation (83.3% vs. 33.3% for non-preeclamptics, (n = 78; p = 0.003). GlyFn positive or high positive was seen in 13/16 (81%) and in 35/68 (51.5%), yielding a sensitivity of 81%, a specificity of 49%, a positive predictive value of 27%, and a negative predictive value of 92%. GlyFn positive or high positive was also associated with preterm birth < 37 weeks in singleton pregnancy non-preeclamptic patients. Preterm birth occurred in 4.8% of those with normal GlyFn, in 26.7% with positive GlyFn, and in 50% of those with high GlyFn in singleton gestations without preeclampsia (p = 0.008). CONCLUSION: The ability to use this test in a POC format provides a method for practitioners to quickly determine risk for preeclampsia in their pregnant patients and offers an affordable alternative, as a single analyte to other diagnostic or screening tests that require laboratory-based testing or ultrasound equipment. Independent of preeclampsia, an elevated GlyFn was also correlated with preterm delivery and requires further study.
650    _2
$a lidé $7 D006801
650    12
$a preeklampsie $x diagnóza $7 D011225
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a těhotenství $7 D011247
650    12
$a fibronektiny $x analýza $7 D005353
650    _2
$a dospělí $7 D000328
650    _2
$a prospektivní studie $7 D011446
650    _2
$a pilotní projekty $7 D010865
650    _2
$a biologické markery $x analýza $7 D015415
650    _2
$a imunoanalýza $x metody $7 D007118
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a vyšetření u lůžka $7 D019095
650    _2
$a point of care testing $7 D000067716
650    _2
$a gestační stáří $7 D005865
650    _2
$a glykované proteiny $7 D000093844
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Arduini, Maurizio $u Obstetrics and Gynecology Department, S. Maria della Misericordia Hospital, Perugia, Italy
700    1_
$a Bartha, Jose Luis $u Department of Obstetrics and Gynecology, University Hospital La Paz, Universidad Autónoma de Madrid, Spain
700    1_
$a Froeliger, Alizee $u Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France
700    1_
$a Jorgensen, Jan Stener $u Department of Gynecology and Obstetrics, Research Unit of Gynecology and Obstetrics, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
700    1_
$a Kacerovsky, Marian $u Biomedical Research Center, University Hospital Hradec Králové, Hradec Králové, Czech Republic $u Department of Obstetrics and Gynecology, Hospital Most, Ústí nad Labem, Czech Republic
700    1_
$a Stanirowski, Pawel $u Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000174457546
700    1_
$a Wielgos, Miroslaw $u Department of Obstetrics and Perinatology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland
700    1_
$a Gao, Lina $u Biostatistics Shared Resources, Knight Cancer Institute, and Bioinformatics & Biostatistics Core, Oregon National Primate Research Center, Oregon Health & Science University
700    1_
$a Gravett, Michael G $u Departments of Obstetrics and Gynecology and of Global Health, University of Washington, Seattle, WA, USA
773    0_
$w MED00007048 $t Journal of maternal-fetal & neonatal medicine $x 1476-4954 $g Roč. 38, č. 1 (2025), s. 2474674
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40051335 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134922 $b ABA008
999    __
$a ok $b bmc $g 2310942 $s 1246336
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 38 $c 1 $d 2474674 $e 20250307 $i 1476-4954 $m Journal of maternal-fetal & neonatal medicine $n J Matern Fetal Neonatal Med $x MED00007048
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...